Status:
COMPLETED
Predictive Value of CHA2DS2VASC Score for Contrast-induced Nephropathy After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients
Lead Sponsor:
Cairo University
Conditions:
Acute ST Segment Elevation Myocardial Infarction
Eligibility:
All Genders
18-80 years
Brief Summary
Contrast induced acute kidney injury has commonly been referred to as contrast induced nephropathy (CIN) defined as an increase in serum creatinine ≥25% or ≥0.5 mg/dl from baseline within 48-72 hours ...
Detailed Description
\- Methodology in details: All patients with ST elevation myocardial infarction who meets the inclusion criteria will be subjected to: A. Full history taking: including age, sex, history of DM, HTN,...
Eligibility Criteria
Inclusion
- All patients with ST elevation myocardial infarction undergoing primary PCI between 18 and 80 years old will be enrolled in this study
Exclusion
- Patients known to have ESRD.
- Patient refusal to participate or withdrawal of consent
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04730778
Start Date
April 1 2021
End Date
April 15 2023
Last Update
September 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasralainy hospital, faculty of medicine, Cairo university
Cairo, Egypt, 11562